Skip to main content

agalsidase beta (Fabrazyme®)

 

Following a full submission

AWMSG advice
Status: Recommended

Agalsidase beta (Fabrazyme®) should be endorsed within NHS Wales for the treatment of Fabry disease in accordance with the licensed indication with the following restrictions:

AWMSG recommends that:

  1. Patients receiving agalsidase beta (Fabrazyme®) will be entered into the Fabry registry.
  2. Treatment will be administered under the supervision of a physician experienced in the management of Fabry disease or other inherited metabolic diseases.
  3. Treatment will be administered according to agreed guidelines at appropriate centres.
 Final Recommendation: agalsidase beta (Fabrazyme) 12 (PDF, 13Kb)

Medicine details
Medicine name agalsidase beta (Fabrazyme®)
Formulation 5 mg and 32 mg powder for concentrate for solution for infusion
Reference number 12
Indication

Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency)
Company Genzyme Therapeutics
BNF chapter Nutrition & blood
Assessment type Full
Status Recommended
AWMSG meeting date 02/10/2006
Ratification by Welsh Government 25/10/2006
Date of issue 31/12/2006
Follow AWTTC: